

## Scientific Programme

*Thursday, January 31, 2019*

### Opening Talk

Time	Presentation Title	Speaker
08:30 – 09:00	Opening and Objectives	W. Oyen, G. Chételat

### Track 1

*Thursday, January 31, 2019*

### PET as Part of the Biomarker Toolbox for Early Clinical Diagnosis of Alzheimer Disease (AD)

Chairpersons: J. Arbizu / V. Garibotto / P. Scheltens / S. Minoshima

Time	Presentation Title	Speaker
09:00 – 09:20	Unmet Need for Early Diagnosis of Prodromal AD	B. Dubois
09:25 – 09:45	Contribution of MRI for Early Diagnosis of AD	G. Frisoni
09:50 – 10:10	Contribution of CSF for Early Diagnosis of AD	H. Zetterberg
10:15 – 10:35	Contribution of PET for Early Diagnosis of AD	S. Minoshima
11:00 – 11:10	Controversy: Early Diagnosis of AD – PET in the Initial Work-Up	J. Arbizu
11:10 – 11:35	Controversy: Against	P. Scheltens
11:40 – 12:05	Controversy: In Favour	F. Nobili
12:05 – 12:15	Questions & Answers	all
12:15 – 13:00	Consensus on Imaging for Early Diagnosis of AD	S. Minoshima, J. Arbizu, V. Garibotto

## Track 2

*Thursday, January 31, 2019*

### Molecular Imaging in the Differential Diagnosis of Dementia

Chairpersons: S. Morbelli / J. Arbizu

Time	Presentation Title	Speaker
14:00 – 14:25	Contribution of MRI	F. Agosta
14:30 – 14:55	Unmet Clinical Needs and Contribution of PET in Frontotemporal Lobar Degeneration	G. Rabinovici
15:00 – 15:25	Unmet Clinical Needs and Contribution of Molecular Imaging in Parkinsonian Syndromes	D. J. Brooks
16:00 – 16:10	Controversy: FDG-First versus Amyloid-First for Differential Dementia Diagnosis?	J. Arbizu
16:15 – 16:35	Controversy: FDG PET-First	D. Perani
16:35 – 17:00	Controversy: Amyloid PET-First	R. Ossenkoppele
17:00 – 17:10	Questions & Answers	all
17:10 – 18:00	Consensus on Molecular Imaging for Differential Dementia Diagnosis	J. Arbizu, S. Morbelli

## Track 3

Friday, February 1, 2019

### Clinical Acceptance of Amyloid Imaging

Chairpersons: V. Garibotto / A. Drzezga

Time	Presentation Title	Speaker
	<b>Round Table: Evidence for a Routine Use of Amyloid Markers</b>	
09:00 – 09:30	Introduction: The Current Status of Amyloid Markers (PET and CSF) Reimbursement and the Point of View of the Payers and the Industry in the IMI-2 Initiative	G. Frisoni
09:35 – 09:50	Clinical Use of "Freely Accessible" Amyloid Markers – The Example of Sweden	A. Nordberg
09:55 – 10:15	The Point of View of the Patients and the Families	M. C. Carrillo
10:20 – 10:40	The Point of View of the Scientific Community	S. Landau
11:00 – 11:20	Ongoing Studies to Provide Answers – AMYPAD and Other European Initiatives	F. Barkhof
11:25 – 11:45	Ongoing Studies to Provide Answers – IDEAS and Other Collaborative Efforts Worldwide	G. Rabinovici
	<b>Discussion and Consensus</b>	
11:50 – 12:30	Consensus on Clinical Use of Amyloid Markers	A. Drzezga
12:30 – 13:00	Consensus on Research Priorities	V. Garibotto

## Track 4

Friday, February 1, 2019

### The Use of PET in Dementia Research

Chairpersons: H. Barthel / G. Chételat / A. Drzezga

Time	Presentation Title	Speaker
14:00 – 14:20	Impact of Brain Connectivity and Reserve in Dementia	G. Chételat
	<b>Round Table: The Complementarity of Neuroimaging Techniques in Clinical Trials</b> <b>i) to Enrich Target Populations and</b> <b>ii) to Monitor Drug Effects</b>	
14:25 – 14:45	FDG-PET Imaging	K. Herholz
14:50 – 15:10	MR Imaging	P. Scheltens
15:15 – 15:35	Amyloid and Tau-PET Imaging	V. Villemagne
16:00 – 16:10	Controversy: Guidelines for Research Criteria in Preclinical AD: Should Amyloid be Considered as the Lead Biomarker in the Hierarchy?	G. Chételat
16:15 – 16:35	Controversy: In Favour	C. Jack
16:40 – 17:00	Controversy: Against	A. Fjell
17:00 – 17:35	Consensus on Hierarchy of Biomarkers in Preclinical AD	G. Chételat
17:40 – 18:00	Do we Need Multimodal Imaging?	A. Drzezga

## Track 5

*Saturday, February 2, 2019*

### New Developments and Methodology

Chairpersons: I. Law / E. van de Giessen / H. Barthel

Time	Presentation Title	Speaker
09:00 – 09:20	Imaging of Neuroinflammation in Neurodegeneration – What does it Add to Our Understanding?	D. J. Brooks
09:25 – 09:45	Principles of Absolute PET Quantification for Monitoring Longitudinal Treatment Response?	A. Lammertsma
09:50 – 10:10	Amyloid and Tau Imaging: Centiloid, Centaur, and Clinical Use	V. Villemagne
10:15 – 10:35	PET-Tau Imaging for Early and Differential Diagnosis of AD	O. Hansson
11:00 – 11:20	Standards for In-Vitro Validation of PET Tracers in Neurodegeneration	A. Nordberg
11:25 – 11:55	Hybrid PET/MRI: Has it Developed the Dementia Field?	H. Barthel
12:00 – 12:20	Issues in Quantification for Neurological PET Studies	B. Hutton
12:25 – 13:00	Discussion: What else do We Need for Progress? (New Tracers, Artificial Intelligence, etc.)	I. Law, E. van de Giessen